Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Sales of marketed products, particularly Pivlaz® and Quviviq®, remained strong, while milestone income in research and development revenue increased to 8 items from 5 in the same period of the previous year. Expenses also declined as a result of focusing research and development on selected areas and reducing costs. Meanwhile, the company recorded restructuring costs and impairment losses on goodwill and lease assets.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥18,910 million (YoY +25.3%) |
| Operating profit | ¥1,881 million |
| Ordinary income | ¥1,399 million |
| Profit attributable to owners of the parent | ¥1,591 million |
| Net income per share | ¥17.54 |
| Equity ratio | End of the current fiscal period 49 / End of previous period 45.3 |
| Total assets | ¥132,381 million |
| Net assets | ¥64,803 million |
| Cash flows from operating activities | ¥3,975 million |
| Cash flows from investing activities | ¥-4,347 million |
| Cash flows from financing activities | ¥-2,576 million |
| Cash and cash equivalents at end of period | ¥17,748 million |
| Full-year earnings forecast | Net Sales 33,800～48,800 / Operating profit 700～15,700 / Ordinary income Not disclosed / Net income Not disclosed |
| Annual Dividend Forecast | ¥0 → ¥0（0.0） |
| Depreciation and amortization | ¥856 million |
| Impairment loss | ¥1,214 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Not disclosed / Excluded Not disclosed / Summary Material changes in the scope of consolidation during the interim period: None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (scheduled to be held online; target audience: Not disclosed) |
| Issued Shares at Period-End | 92,614,159 |
| Treasury Shares at Period-End | 1,238,381 |
| Factors Behind Changes in Business Performance | Sales of marketed products, particularly Pivlaz® and Quviviq®, remained strong, while milestone income in research and development revenue increased to 8 items from 5 in the same period of the previous year. Expenses also declined as a result of focusing research and development on selected areas and reducing costs. Meanwhile, the company recorded restructuring costs and impairment losses on goodwill and lease assets. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main factors behind the improvement in performance were strong sales of marketed products, including Quviviq®, increased milestone income from existing partners, a more focused approach to research and development areas, and expense reductions. Meanwhile, the company recorded ¥467 million in restructuring costs and ¥1,214 million in impairment losses on goodwill and lease assets.